Aim: Large-scale clinical studies on chemotherapy-induced nausea and vomiting (CINV) induced by highly emetogenic chemotherapy (HEC) showed that antiemetic therapy with a 3-drug combination of aprepitant, granisetron and dexamethasone (AGD) or a 2-drug combination of palonosetron and dexamethasone (PD) were superior to conventional antiemetic therapy a 5HT3 receptor antagonist and dexamethasone. But the AGD and PD regimens have not been compared. We performed a randomized crossover trial to compare the efficacy of AGD and PD in HEC. Methods: The subjects were patients with esophageal or gastric cancer who underwent HEC including ≥60 mg/m 2 cisplatin as first-line treatment. Patients were randomly assigned into groups treated with AGD (oral aprepitant 125 mg on day 1, 80 mg on days 2-3; intravenous granisetron 3 mg on day 1; intravenous dexamethasone (D) 6.6 mg on day 1 and oral D 4 mg on days 2-3) or PD (intravenous palonosetron 0.75 mg on day 1; intravenous D 13.2 mg on day 1 and oral D 8 mg on days 2-3). The
antiemetic therapies were crossed-over in the second course. The primary endpoint was a complete response (CR: defined as no emetic episodes and no requirement for rescue medication) in the overall phase (0-120 h) during the first course. The planned sample size of 80 patients provided 80% power to detect a 30% improvement in CR with a two-sided alpha of 0.05. Results: Eighty-fifth patients were enrolled in the study and 84 were evaluable. Baseline factors were well-balanced between the two groups. The CR rate did not differ significantly between the two groups, but the frequency of no vomiting was significantly higher in the AGD group (Table 1) . Regarding patient's preference after the second course, 41.0% of patients preferred AGD, 19.7% preferred PD, and 39.3% indicated no preference. Based on a QOL survey, the frequency of no or minimal impact on daily life in the vomiting domain was significantly higher in the AGD group (79.1% vs. 53.7%; p = 0.014). Conclusions: The primary endpoint of CR was not achieved, but AGD combination therapy seems to more effective than PD therapy for prevention of HEC-induced CINV.
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